Last Updated on February 10, 2021 by The Health Master
Global pharma major Lupin Limited has received approval for its tavaborole topical solution, 5%, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Kerydin topical solution, 5%, of Anacor Pharmaceuticals, Inc.
The product will be manufactured at Lupin’s facility in Pithampur, India.
Tavaborole topical solution, 5%, is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to trichophyton rubrum or trichophyton mentagrophytes.
Tavaborole topical solution had estimated annual sales of US$ 76 million in the US, according to IQVIA MAT December 2020.
Also read | Alembic Pharma gets 5 observations from USFDA
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
Follow and connect with us on Facebook and Linkedin
Go to main website, click here
Subscribe for daily free updates, click here
For daily free updates on WhatsApp, click here
